

AN 1992:22038020 BIOTECHNO

AB The over-expression of the proto-oncogene HER-2 (c-erbB-2/neu) in ovarian, endometrial and mammary carcinoma is an important indicator for poor prognosis. We have previously shown in 3 out of 4 ovarian carcinoma cell lines an interferon-gamma (IFN- γ)-mediated reduction in HER-2 specific protein and RNA levels. The oncogene expression was lowered only in the ovarian carcinoma cell lines but not in 3 IFN- γ -sensitive human breast cancer cell lines. We extended our observations also to IFN type I, α and ω . The expression of the oncogene was measured by both the p185(HER-2) ELISA and in selected cases by a living cell radioimmunoassay using the monoclonal antibody (MAB) 4D5 against the extracellular domain. Both IFN types reduced the expression of HER-2 in the ovarian carcinoma cell lines OVCAR-3, HTB-77, 2774 and SKOV-6, and in the SKUT-2 endometrial carcinoma cells. In contrast, SKOV-8 human ovarian carcinoma cells were sensitive for both IFN- types regarding proliferation, but only IFN- γ reduced proto-oncogene expression. In the SKBR-3 human mammary carcinoma cells, neither IFN- type had an effect on HER-2 expression. The **antibodies** 4D5, 7C2, 3E8, and 3H4 which bind to the extracellular domain of p185(HER-2) protein specifically inhibited anchorage-independent growth of SKBR-3 and HTB-77 cells. Expression of the oncogene HER-2 is the leading prognostic factor in ovarian cancer. Its modulation might represent a mechanism by which IFN-s inhibit cell proliferation.

L10 ANSWER 3 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1988:18169754 BIOTECHNO

TITLE: Rapid titration of bovine, caprine and human RS virus by a micro-immunoperoxidase assay using a monoclonal antibody and a permissive ovine kidney cell line

AUTHOR: Belanger F.; Alain R.; Payment P.; Lecomte J.; Trudel M.

CORPORATE SOURCE: Institut Armand-Frappier, Universite du Quebec, Centre de Recherche en Virologie, Ville de Laval, Que. H7N 4Z3, Canada.

SOURCE: Journal of Virological Methods, (1988), 20/2 (101-107)
CODEN: JVMEDH ISSN: 0166-0934

DOCUMENT TYPE: Journal; Article

COUNTRY: Netherlands

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1988:18169754 BIOTECHNO

AB An indirect immunoperoxidase micro-assay, using a continuous cell line derived from ovine kidney cells (OK) and a previously characterized monoclonal **antibody** (7C2), specific for an exposed and highly conserved epitope of the fusion protein of different strains of RS virus, was used advantageously to rapidly titrate bovine, caprine and human strains of RSV by either quantal (TCID₅₀) or plaque forming assays. Virus titers, obtained in less than 36 h, were in agreement with those obtained by the conventional plaque assays which required an incubation period of 4 days or more. This assay is also applicable to micro-neutralization of fusion inhibition assays for testing serum or screening monoclonal antibodies.

L10 ANSWER 4 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1987:18019597 BIOTECHNO

TITLE: Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization

AUTHOR: Trudel M.; Nadon F.; Seguin C.; Payment P.; Talbot P.J.

CORPORATE SOURCE: Centre de Recherche en Virologie, Institute Armand-Frappier, Universite du Quebec, Ville de Laval, Que. H7N 4Z3, Canada.

SOURCE: Canadian Journal of Microbiology, (1987), 33/10
(933-938)
CODEN: CJMIAZ ISSN: 0008-4166
DOCUMENT TYPE: Journal; Article
COUNTRY: Canada
LANGUAGE: English
SUMMARY LANGUAGE: French; English
AN 1987:18019597 BIOTECHNO
AB Competition experiments and biological assays with a panel of 15 monoclonal antibodies confirmed the presence of a least four antigenic sites on the fusion protein of human respiratory syncytial virus, three of which were involved in virus neutralization. One antigenic site, recognized by two strongly neutralizing antibodies, was conserved after reduction and denaturation and shown by immunoblotting to be localized on the F.sub.1 fragment of the fusion protein. Cleavage of this protein with staphylococcal protease V8 or papain produced a series of smaller peptides from 11 to 7 kilodaltons that retained this important neutralization determinant. Compared with the other neutralization sites, the epitope defined by monoclonal **antibody 7C2** thus appears as the major neutralization epitope. Our peptide mapping results support the hypothesis that this major epitope is composed of a continuous sequence on the viral genome.

L10 ANSWER 5 OF 5 LIFESCI COPYRIGHT 2004 CSA on STN
ACCESSION NUMBER: 83:27789 LIFESCI
TITLE: A monoclonal antibody to kidney endopeptidase-24.11. Its application in immunoabsorbent purification of the enzyme and immunofluorescent microscopy of kidney and intestine.
AUTHOR: Gee, N.S.; Matsas, R.; Kenny, A.J.
CORPORATE SOURCE: Dep. Biochem., Univ. Leeds, Leeds LS2 9JT, UK
SOURCE: BIOCHEM. J., (1983) vol. 214, no. 2, pp. 377-386.
DOCUMENT TYPE: Journal
FILE SEGMENT: M; L
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Hybridoma methodology has been used to produce a monoclonal **antibody**, GK 7C2, that binds specifically to microvillar endopeptidase-24.11 (EC 3.4.24.11). It was used to purify the enzyme from pig kidney. The enzyme had an apparent M sub(r) of 90,000 and contained endopeptidase activity sensitive to phosphoramidon. The identity was confirmed by immunoabsorbent purification of endopeptidase-24.11 by a column to which GK 7C2 had been attached. The endopeptidase, purified in a yield of 40%, was electrophoretically homogeneous and of specific activity comparable with that purified by other means. Fluorescence microscopy established that GK 7C2 bound specifically to the luminal membranes of kidney tubules and the intestinal mucosa. Thus endopeptidase-24.11 is located in the brush-border membranes of both cell types.

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:50:30 ON 08 SEP 2004

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'AGRICOLA' ENTERED AT 16:50:48 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:50:48 ON 08 SEP 2004

COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:50:48 ON 08 SEP 2004

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> (AMER5 or 7C2)(3A)antibody

L1	0	FILE AGRICOLA
L2	4	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	2	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES

L9	7	(AMER5 OR 7C2)(3A) ANTIBODY
----	---	-----------------------------

=> dup rem

ENTER L# LIST OR (END):19

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L9

L10	5	DUP REM L9 (2 DUPLICATES REMOVED)
-----	---	-----------------------------------

=> d l10 ibib abs total

L10 ANSWER 1 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1992:22179176 BIOTECHNO
TITLE: Radiolabeled antibody targeting of the HER-2/neu
oncoprotein
AUTHOR: De Santes K.; Slamon D.; Anderson S.K.; Shepard M.;
Fendly B.; Maneval D.; Press O.
CORPORATE SOURCE: University of Washington, Cancer Center, Mailstop
RC-08, Seattle, WA 98195, United States.
SOURCE: Cancer Research, (1992), 52/7 (1916-1923)
CODEN: CNREA8 ISSN: 0008-5472
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1992:22179176 BIOTECHNO

AB The HER-2/neu oncogene encodes a M(r) 185,000 transmembrane
phosphoglycoprotein which is overexpressed in 25-35% of breast and
ovarian neoplasms and portends a poor prognosis. We have studied the
feasibility of targeting this oncoprotein, designated p185, with
radioiodinated murine monoclonal **antibodies** (muMABs) 4D5 and
7C2, which recognize distinct epitopes on its extracellular
domain. The rates of internalization and catabolism of these antibodies
were analyzed by cellular radioimmunoassay and electron microscopy. After
binding to NIH3T3 HER-2/neu cells, which show high surface expression of
p185, the muMABs were endocytosed via coated pits, routed to lysosomes,
and degraded. Approximately 44% of .sup.1.sup.2.sup.5I-4D5 and 39% of
.sup.1.sup.2.sup.5I- 7C2 were catabolized by tumor cells after 24 h. The
biodistribution of radiolabeled 4D5 and 7C2 were evaluated in beige/nude
mice bearing s.c. NIH3T3 HER-2/neu grafts. A high specificity of
localization was seen with tumor:organ ratios of activity generally
ranging from 5:1 to 30:1. However, the percentage injected dose of
radioactivity per gram of tumor declined sharply from 25% at 24 h to 5%
at 120 h postinjection. Treating the animals with 400-700 µCi
.sup.1.sup.3.sup.1I-4D5 caused a marked inhibition of tumor growth,
although no mice were cured. Unlabeled 4D5 had no effect on tumor
progression in this model, but administering 400-700 µCi of
.sup.1.sup.3.sup.1I-DA4-4, an isotype- matched irrelevant muMAB, resulted
in an intermediate degree of growth retardation. Analysis of kinetic
blood data and whole-body time-activity curves indicated that the
irrelevant conjugate remained in the body 2-3 times longer than
.sup.1.sup.3.sup.1I-4D5. Radioiodinated anti-HER-2/neu muMABs are
attractive agents for radioimmunodiagnosis and radioimmunotherapy of
aggressive HER- 2/neu-positive breast and ovarian carcinomas, but
effective strategies for retarding intratumoral catabolism may be
necessary to optimize their clinical utility.

L10 ANSWER 2 OF 5 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1992:22038020 BIOTECHNO
TITLE: Effects of interferons on the expression of the
proto-oncogene HER-2 in human ovarian carcinoma cells
AUTHOR: Marth C.; Cronauer M.V.; Doppler W.; Ofner D.; Ullrich
A.; Daxenbichler G.
CORPORATE SOURCE: Dept. Obstetrics/Gynecology, Innsbruck University
Clinic, Anichstrasse 35, A-6020 Innsbruck, Austria.
SOURCE: International Journal of Cancer, (1992), 50/1 (64-68)
CODEN: IJCNAA ISSN: 0020-7136
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal64lcxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus
NEWS	6	May 27 CPlus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CPlus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS	JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:06:26 ON 08 SEP 2004

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:06:37 ON 08 SEP 2004

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> HER2(3A) (ECD) (12A)antibody

L1	0	FILE AGRICOLA
L2	2	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	1	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES

L9	4	HER2(3A) (ECD) (12A) ANTIBODY
----	---	-------------------------------

=> dup rem

ENTER L# LIST OR (END):19

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L9

L10	2	DUP REM L9 (2 DUPLICATES REMOVED)
-----	---	-----------------------------------

=> d l10 ibib abs total

L10 ANSWER 1 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance
to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas
A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras
B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12
de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40
reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 2000:30399203 BIOTECHNO

AB To test the hypothesis of an association between HER2, and chemotherapy
resistance, we performed a prospective assessment of the predictive value
of the circulating HER2 extracellular domain (ECD) in patients with
advanced breast carcinoma in the setting of a multicenter Phase II trial
using paclitaxel and doxorubicin. Serum samples were collected from 58
patients with metastatic breast carcinoma before first-line chemotherapy
for advanced disease, and the levels of circulating **HER2**
ECD were measured using an enzyme immunoassay.
Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11
was used to assess the overexpression of HER2 in the primary tumors. When
450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD
levels. Elevated levels of circulating HER2 ECD were associated with the
expression of HER2 in the primary tumor tissue and with the metastatic
tumor burden (evaluated with the marker CA 15-3; $P = 0.032$ and $P = 0.002$,
respectively) but not with variables such as menopausal status, stage at
diagnosis, previous adjuvant therapy, or the number of metastatic sites.
The levels of circulating HER2 ECD correlated inversely with the response
to treatment. The probability of obtaining a complete response to
chemotherapy was significantly lower ($P = 0.021$) in patients with
elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared
with patients with nonelevated HER2 (26%; 95% confidence interval,
12-45%). In addition, the duration of clinical response was significantly
shorter in patients with elevated HER2 ECD, compared with the cases with
nonelevated HER2 (7.5 versus 11 months; $P = 0.035$). In conclusion,
elevated levels of circulating HER2 ECD in patients with metastatic
breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin
chemotherapy combination. We suggest that the poor response rate
associated with HER2 expression in advanced breast cancer may not be
reversed by aggressive chemotherapy alone.

L10 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1990:20263864 BIOTECHNO
TITLE: ELISA for quantitation of the extracellular domain of
p185(HER2) in biological fluids
AUTHOR: Sias P.E.; Kotts C.E.; Vetterlein D.; Shepard M.; Wong
W.L.T.
CORPORATE SOURCE: Immunology Research and, Assay Technologies, Genentech
Inc., 460 Point San Bruno Boulevard, South San
Francisco, CA 94080, United States.
SOURCE: Journal of Immunological Methods, (1990), 132/1
(73-80)

CODEN: JIMMBG ISSN: 0022-1759

DOCUMENT TYPE:

Journal; Article

COUNTRY:

Netherlands

LANGUAGE:

English

SUMMARY LANGUAGE:

English

AN 1990:20263864 BIOTECHNO

AB The HER2/neu proto-oncogene encodes a receptor that belong to the tyrosine-specific protein kinase family. Amplification of the HER2 gene in patients with breast and ovarian cancer has been shown to predict poorer survival rates. In order to understand the role of HER2 in malignant and normal cells, it is necessary to devise assays that can quantitate expression levels of the HER2 gene product (p185(HER2)) in production samples, biopsy specimens and biological fluids. We have developed a simple, quantitative ELISA that uses two monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185(HER2) (HER2 ECD). The assay has a detection range of 0.25-120 ng/ml, is precise and sensitive. The ability of this assay to detect biologically active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay ($r = 0.92$). The sandwich ELISA can also accurately quantitate rHER2 ECD in mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as antigen for immunotherapy and in patients which 'shed' receptor.

TITLE

AUTHOR(S): Increased levels of circulating **HER2 ECD**
in response to anti-HER2 **antibody** therapy.
Park, J. W. [Reprint author]; Colbern, G.; Nuijens, A.;
Baselga, J.; McMillan, A.; Henderson, I. C.;
Papahadjopoulos, D.; Benz, C. C.
CORPORATE SOURCE: UCSF, San Francisco, CA 94143, USA
SOURCE: Breast Cancer Research and Treatment, (Oct., 1997) Vol. 46,
No. 1, pp. 67. print.
Meeting Info.: 20th Annual San Antonio Breast Cancer
Symposium. San Antonio, Texas, USA. December 3-6, 1997.
CODEN: BCTRD6. ISSN: 0167-6806.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 30 Jan 1998
Last Updated on STN: 30 Jan 1998

L26 ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
DUPLICATE 1

ACCESSION NUMBER: 1997:33318 BIOSIS

DOCUMENT NUMBER: PREV199799339721

TITLE: 186-Re-labeled antibodies to p185-HER2 as HER2-targeted
radioimmunopharmaceutical agents: Comparison of physical
and biological characteristics with 125I and 131I-labeled
counterparts.

AUTHOR(S): Kotts, C. E. [Reprint author]; Su, F. M.; Leddy, C.; Dodd,
T.; Scates, S.; Shalaby, M. R.; Wirth, C. M.; Giltinan, D.;
Schroff, R. W.; Fritzberg, A. R.; Shepard, H. M.; Slamon,
D. J.; Hutchins, B. M.

CORPORATE SOURCE: Genentech Inc., Mail Zone 65, 460 Point San Bruno Blvd., S.
San Francisco, CA 94080, USA

SOURCE: Cancer Biotherapy and Radiopharmaceuticals, (1996) Vol. 11,
No. 2, pp. 133-144.
ISSN: 1084-9785.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 28 Jan 1997

Last Updated on STN: 28 Jan 1997

AB Overexpression of the HER2/neu protooncogene has been shown to correlate
with poor clinical prognosis. A murine monoclonal **antibody**
(4D5) directed against the extracellular domain (ECD) of p185-
HER2 has been shown to inhibit in vitro and in vivo growth of
carcinomas overexpressing HER2 and has been humanized (rhuMab HER2). The
objective of the study was the identification of an agent which might be
useful for in vitro studies, tumor imaging and/or radioimmunotherapy by
linking beta-emitting radionuclides to these HER2-targeted antibodies.
Murine 4D5 and humanized rhuMab HER2 were radiolabeled with 125I, 131I or
186Re. Physical characteristics (TCA precipitability, SDS-PAGE, size
exclusion chromatography), binding affinities to the **HER2 ECD** (in an ELISA
and on SK-BR-3 cells) and antiproliferative activities of the radiolabeled
antibodies were determined. Although 131I-4D5 and 131I-rhuMab HER2
usually retained gt 85% ECD binding, they exhibited increased aggregation
and fragment content, drastically reduced antiproliferative activities and
poor stability upon storage at 4 degree C. For these antibody
preparations, conservation of binding did not necessarily correlate with
preservation of bioactivity indicating the importance of bioactivity
determinations in radiolabeled antibody studies. Conversely, 4D5 and
rhuMab HER2 labeled with 125I or 186Re maintained physical properties, ECD
binding, antiproliferative activities and were stable upon storage at 4
degree C for at least 8 days. The superior retention of physical and
biological characteristics of 186Re-labeled 4D5 and rhuMab HER2 compared
with their 131I-labeled counterparts suggests the potential for their use
as radioimaging and radioimmunotherapeutic agents in the treatment of HER2

motivation

=> dup rem
ENTER L# LIST OR (END):120-23
PROCESSING COMPLETED FOR L20
PROCESSING COMPLETED FOR L21
PROCESSING COMPLETED FOR L22
PROCESSING COMPLETED FOR L23
L26 4 DUP REM L20-23 (3 DUPLICATES REMOVED)

=> d 126 bib abs total

L26 ANSWER 1 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2000217009 EMBASE

TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.

CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain. rcolomer@hdoc.insalud.es

SOURCE: Clinical Cancer Research, (2000) 6/6 (2356-2362).

Refs: 40

ISSN: 1078-0432 CODEN: CCREF4

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 005 General Pathology and Pathological Anatomy

016 Cancer

022 Human Genetics

030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating HER2 ECD were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal antibody CB11 was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; $P = 0.032$ and $P = 0.002$, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower ($P = 0.021$) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; $P = 0.035$). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L26 ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
ACCESSION NUMBER: 1998:69783 BIOSIS
DOCUMENT NUMBER: PREV199800069783

overexpressing tumors.

L26 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 1990:568423 CAPLUS

DOCUMENT NUMBER: 113:168423

TITLE: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids

AUTHOR(S): Sias, Patricia E.; Kotts, Claire E.; Vetterlein, David; Shepard, Mike; Wong, Wai Lee T.

CORPORATE SOURCE: Dep. Immunol., Genentech Inc., So., San Francisco, CA, 94080, USA

SOURCE: Journal of Immunological Methods (1990); 132(1), 73-80
CODEN: JIMMBG; ISSN: 0022-1759

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The HER2/neu proto-oncogene encodes a receptor that belongs to the tyrosine-specific protein kinase family. A simple, quant. ELISA was developed that uses 2 monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185HER2 (**HER2 ECD**). The assay has a detection range of 0.25-120 ng/mL, is precise and sensitive. The ability of this assay to detect biol. active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay. The sandwich ELISA can also accurately quantitate rHER2 ECD in a mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as an antigen for immunotherapy and in patients which shed receptor.

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:06:26 ON 08 SEP 2004

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'AGRICOLA' ENTERED AT 16:06:37 ON 08 SEP 2004

FILE 'BIOTECHNO' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:06:37 ON 08 SEP 2004

COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 16:06:37 ON 08 SEP 2004

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

=> HER2(3A) (ECD) (12A) antibody

L1	0	FILE AGRICOLA
L2	2	FILE BIOTECHNO
L3	0	FILE CONFSCI
L4	0	FILE HEALSAFE
L5	0	FILE IMSDRUGCONF
L6	1	FILE LIFESCI
L7	0	FILE MEDICONF
L8	1	FILE PASCAL

TOTAL FOR ALL FILES

L9	4	HER2(3A) (ECD) (12A) ANTIBODY
----	---	-------------------------------

=> dup rem

ENTER L# LIST OR (END):19

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L9

L10	2	DUP REM L9 (2 DUPLICATES REMOVED)
-----	---	-----------------------------------

=> d l10 ibib abs total

L10 ANSWER 1 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance
to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas
A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras
B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12
de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40
reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 2000:30399203 BIOTECHNO

AB To test the hypothesis of an association between HER2, and chemotherapy
resistance, we performed a prospective assessment of the predictive value
of the circulating HER2 extracellular domain (ECD) in patients with
advanced breast carcinoma in the setting of a multicenter Phase II trial
using paclitaxel and doxorubicin. Serum samples were collected from 58
patients with metastatic breast carcinoma before first-line chemotherapy
for advanced disease, and the levels of circulating **HER2**
ECD were measured using an enzyme immunoassay.
Immunohistochemistry with anti-HER2 monoclonal **antibody** CB11
was used to assess the overexpression of HER2 in the primary tumors. When
450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD
levels. Elevated levels of circulating HER2 ECD were associated with the
expression of HER2 in the primary tumor tissue and with the metastatic
tumor burden (evaluated with the marker CA 15-3; $P = 0.032$ and $P = 0.002$,
respectively) but not with variables such as menopausal status, stage at
diagnosis, previous adjuvant therapy, or the number of metastatic sites.
The levels of circulating HER2 ECD correlated inversely with the response
to treatment. The probability of obtaining a complete response to
chemotherapy was significantly lower ($P = 0.021$) in patients with
elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared
with patients with nonelevated HER2 (26%; 95% confidence interval,
12-45%). In addition, the duration of clinical response was significantly
shorter in patients with elevated HER2 ECD, compared with the cases with
nonelevated HER2 (7.5 versus 11 months; $P = 0.035$). In conclusion,
elevated levels of circulating HER2 ECD in patients with metastatic
breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin
chemotherapy combination. We suggest that the poor response rate
associated with HER2 expression in advanced breast cancer may not be
reversed by aggressive chemotherapy alone.

L10 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1990:20263864 BIOTECHNO
TITLE: ELISA for quantitation of the extracellular domain of
p185(HER2) in biological fluids
AUTHOR: Sias P.E.; Kotts C.E.; Vetterlein D.; Shepard M.; Wong
W.L.T.
CORPORATE SOURCE: Immunology Research and, Assay Technologies, Genentech
Inc., 460 Point San Bruno Boulevard, South San
Francisco, CA 94080, United States.
SOURCE: Journal of Immunological Methods, (1990), 132/1
(73-80)

CODEN: JIMMBG ISSN: 0022-1759

DOCUMENT TYPE: Journal; Article
COUNTRY: Netherlands
LANGUAGE: English
SUMMARY LANGUAGE: English

AN 1990:20263864 BIOTECHNO

AB The HER2/neu proto-oncogene encodes a receptor that belong to the tyrosine-specific protein kinase family. Amplification of the HER2 gene in patients with breast and ovarian cancer has been shown to predict poorer survival rates. In order to understand the role of HER2 in malignant and normal cells, it is necessary to devise assays that can quantitate expression levels of the HER2 gene product (p185(HER2)) in production samples, biopsy specimens and biological fluids. We have developed a simple, quantitative ELISA that uses two monoclonal **antibodies** directed against the extracellular domain of the HER2 gene product, p185(HER2) (HER2 ECD). The assay has a detection range of 0.25-120 ng/ml, is precise and sensitive. The ability of this assay to detect biologically active rHER2 ECD is demonstrated by its correlation to a growth inhibitory bioassay ($r = 0.92$). The sandwich ELISA can also accurately quantitate rHER2 ECD in mouse and monkey serum. This assay should be useful for quantitating low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being used as antigen for immunotherapy and in patients which 'shed' receptor.

=> file .chemistry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.38	11.59

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:10:42 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 16:10:42 ON 08 SEP 2004
Compendex Compilation and Indexing (C) 2004
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 16:10:42 ON 08 SEP 2004
COPYRIGHT (c) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 16:10:42 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> HER2 (3A) (ECD) (12A) antibody
L11 1 FILE CAPLUS
L12 2 FILE BIOTECHNO
L13 0 FILE COMPENDEX
L14 0 FILE ANABSTR
L15 0 FILE CERAB
L16 0 FILE METADEX
L17 16 FILE USPATFULL

TOTAL FOR ALL FILES

L18 19 HER2(3A)(ECD)(12A) ANTIBODY

=> dup rem

ENTER L# LIST OR (END):118

PROCESSING COMPLETED FOR L18

L19 18 DUP REM L18 (1 DUPLICATE REMOVED)

=> d 119 ibib abs total

L19 ANSWER 1 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2004:90568 USPATFULL

TITLE: Method for making humanized antibodies

INVENTOR(S): Carter, Paul J., San Francisco, CA, United States

Presta, Leonard G., San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6719971	B1	20040413
APPLICATION INFO.:	US 2000-705392		20001102 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 146206, now patented, Pat. No. US 6407213, issued on 18 Jun 2002 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ungar, Susan		
ASSISTANT EXAMINER:	Davis, Minh Tam		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	4948		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2003:288214 USPATFULL

TITLE: Protein formulation

INVENTOR(S): Andya, James, Millbrae, CA, UNITED STATES

Cleland, Jeffrey L., San Carlos, CA, UNITED STATES

Hsu, Chung C., Los Altos Hills, CA, UNITED STATES

Lam, Xanthe M., San Francisco, CA, UNITED STATES

Overcashier, David E., El Granada, CA, UNITED STATES

Shire, Steven J., Belmont, CA, UNITED STATES

Yang, Janet Yu-Feng, San Mateo, CA, UNITED STATES

Wu, Sylvia Sau-Yan, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202972	A1	20031030
APPLICATION INFO.:	US 2003-428728	A1	20030502 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-809511, filed on 14 Mar 2001, PENDING Continuation of Ser. No. US 1996-615369, filed on 14 Mar 1996, GRANTED, Pat. No. US 6267958		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 1995-29182P	19950727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1961	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 18 USPATFULL on STN
 ACCESSION NUMBER: 2003:266208 USPATFULL
 TITLE: Antibody fusion proteins: effective adjuvants of protein vaccination
 INVENTOR(S): Penichet, Manuel L., Los Angeles, CA, UNITED STATES
 Dela Cruz, Jay, Inglewood, CA, UNITED STATES
 Peng, Lisan, Tuscon, AZ, UNITED STATES
 Morrison, Sherie L., Los Angeles, CA, UNITED STATES
 PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003187225	A1	20031002
APPLICATION INFO.:	US 2002-118473	A1	20020405 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-366917P	20020321 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	3230	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 18 USPATFULL on STN
 ACCESSION NUMBER: 2003:245137 USPATFULL
 TITLE: CHIMERIC ANTIBODY FUSION PROTEINS FOR THE RECRUITMENT AND STIMULATION OF AN ANTITUMOR IMMUNE RESPONSE
 INVENTOR(S): ROSENBLATT, JOSEPH D., ROCHESTER, NY, UNITED STATES

CHALLITA-EID, PIA, ROCHESTER, NY, UNITED STATES
MORRISON, SHERIE, LOS ANGELES, CA, UNITED STATES
ABBOUD, CAMILLE N., ROCHESTER, NY, UNITED STATES
SHIN, SEUNG-UON, LOS ANGELES, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171551	A1	20030911
APPLICATION INFO.:	US 1998-16743	A1	19980130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-37256P	19970131 (60)
	US 1997-64018P	19971103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL L GOLDMAN ESQ, NIXON PEABODY LLP, CLINTON SQUARE, P O BOX 1051, ROCHESTER, NY, 14603	
NUMBER OF CLAIMS:	76	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	2604	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to chimeric molecules for the stimulation of an anti-tumor immune response to facilitate immune eradication of breast, ovarian and other cancer cells. The chimeric molecules include a binding region which specifically binds to a tumor specific antigen and a chemokine and/or costimulatory ligand. The invention further provides methods for inducing a tumor specific immune response and compositions which can be administered to mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:244864 USPATFULL
TITLE: Compounds that bind HER2
INVENTOR(S): Dennis, Mark S., San Carlos, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171278	A1	20030911
APPLICATION INFO.:	US 2002-196394	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-609721, filed on 30 Jun 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142232P	19990702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	3598	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the novel compounds of the invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as for their use in

research, diagnostic, therapeutic, and prophylactic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2003:225711 USPATFULL

TITLE: Cell and tissue arrays and microarrays and methods of use

INVENTOR(S): Frantz, Gretchen, San Francisco, CA, UNITED STATES
Landon, Trent Harris, San Francisco, CA, UNITED STATES
Peale,, Franklin V., JR., San Carlos, CA, UNITED STATES
Pham, Thinh Quang, San Bruno, CA, UNITED STATES
Stephan, Jean Philippe F., San Carlos, CA, UNITED STATES

Dunlap, Debra Y., Sunnyvale, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157523	A1	20030821
APPLICATION INFO.:	US 2002-300546	A1	20021120 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393551P	20020702 (60)
	US 2002-389610P	20020617 (60)
	US 2002-359563P	20020222 (60)
	US 2002-355205P	20020207 (60)
	US 2001-332635P	20011121 (60)
	US 2001-332293P	20011120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

NUMBER OF CLAIMS: 160

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Page(s)

LINE COUNT: 4103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to biological arrays, biological microarrays, and methods of using the arrays and microarrays to detect the amount and/or presence of a biological molecule in a biological sample. Biological arrays of the invention comprise a solidified, sectionable matrix comprising a plurality of wells disposed therein and one or more biological samples disposed within the plurality of wells, which biological arrays optionally comprise an internal standard preparation and/or an orientation marker. Sections or slices of the biological arrays are mounted on a planar substrate surface to form cellular microarrays of the invention. In alternative cellular microarrays of the invention, the matrix material is a temperature-sensitive material removable from the microarray leaving cellular biological material on the substrate surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2003:225308 USPATFULL

TITLE: Methods for diagnosis and therapy of hematological and virus-associated malignancies

INVENTOR(S): Gaiger, Alexander, Seattle, WA, UNITED STATES
Cheever, Martin A., Mercer Island, WA, UNITED STATES
Hand-Zimmermann, Susan, Redmond, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157119	A1	20030821
APPLICATION INFO.:	US 2002-313644	A1	20021204 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-675904, filed on 28 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-638280, filed on 14 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-404443, filed on 22 Sep 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	2489		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2003:285299 USPATFULL
TITLE: Method for making humanized antibodies
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6639055	B1	20031028
APPLICATION INFO.:	US 2000-705686		20001102 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 146206, now patented, Pat. No. US 6407213 Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Helms, Larry R		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	4651		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2002:171913 USPATFULL
TITLE: Analytical method
INVENTOR(S): Ralph, Peter, Orinda, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002090662 A1 20020711
APPLICATION INFO.: US 2001-921161 A1 20010801 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225433P	20000815 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660	
NUMBER OF CLAIMS:	62	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1268	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The instant invention describes an analytical assay to accurately measure an analyte in the presence of an interfering substance.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:8587 USPATFULL
TITLE: Multivalent antibodies and uses therefor
INVENTOR(S): Miller, Kathy L., San Francisco, CA, UNITED STATES
Presta, Leonard G., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004587	A1	20020110
APPLICATION INFO.:	US 2001-813341	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195819P	20000411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attn: Wendy M. Lee, 1 DNA Way, South San Francisco, CA, 94080-4990	
NUMBER OF CLAIMS:	93	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	45 Drawing Page(s)	
LINE COUNT:	4913	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:144366 USPATFULL
TITLE: Method for making humanized antibodies
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6407213	B1	20020618
APPLICATION INFO.:	US 1993-146206		19931117 (8)
	WO 1992-US5126		19920615

19931117 PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-715272, filed
on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Davis, Minh-Tam
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 82
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 4467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides
are provided, along with methods for their preparation and use.
Consensus immunoglobulin sequences and structural models are also
provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2001:133877 USPATFULL
TITLE: Protein formulation
INVENTOR(S): Andya, James, Millbrae, CA, United States
Cleland, Jeffrey L., San Carlos, CA, United States
Hsu, Chung C., Los Altos Hills, CA, United States
Lam, Xanthe M., San Francisco, CA, United States
Overcashier, David E., El Granada, CA, United States
Shire, Steven J., Belmont, CA, United States
Yang, Janet Yu-Feng, San Mateo, CA, United States
Wu, Sylvia Sau-Yan, San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014326	A1	20010816
	US 6685940	B2	20040203
APPLICATION INFO.:	US 2001-809511	A1	20010314 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-615369, filed on 14 Mar 1996, PENDING Continuation of Ser. No. US 1995-508014, filed on 27 Jul 1995, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-29182P	19960729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1952	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2001:121066 USPATFULL

TITLE: Protein formulation

INVENTOR(S): Andya, James, Millbrae, CA, United States
Cleland, Jeffrey L., San Carlos, CA, United States
Hsu, Chung C., Los Altos Hills, CA, United States
Lam, Xanthe M., San Francisco, CA, United States
Overcashier, David E., El Granada, CA, United States
Shire, Steven J., Belmont, CA, United States
Yang, Janet Yu-Feng, San Mateo, CA, United States
Wu, Sylvia Sau-Yan, San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267958	B1	20010731
APPLICATION INFO.:	US 1996-615369		19960314 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-29182P	19960727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Chan, Christina Y.	
ASSISTANT EXAMINER:	DiBrino, Marianne	
LEGAL REPRESENTATIVE:	Lee, Wendy M.	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	2042	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 14 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2000:50547 USPATFULL

TITLE: Humanized antibodies and methods for making them

INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054297		20000425
APPLICATION INFO.:	US 1995-437642		19950509. (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-934373, filed on 21 Aug 1992, now patented, Pat. No. US 5821337, issued on 13 Oct 1998 which is a continuation-in-part of Ser. No. WO 1992-US5126, filed on 15 Jun 1992 which is a continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Reeyes, Julie E
LEGAL REPRESENTATIVE: Lee, Wendy M.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 5670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 18 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
ACCESSION NUMBER: 2000:30399203 BIOTECHNO
TITLE: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
AUTHOR: Colomer R.; Montero S.; Lluch A.; Ojeda B.; Barnadas A.; Casado A.; Massuti B.; Cortes-Funes H.; Lloveras B.
CORPORATE SOURCE: R. Colomer, Servicio de Oncologia Medica, Hospital 12 de Octubre, 28041 Madrid, Spain.
E-mail: rcolomer@hdoc.insalud.es
SOURCE: Clinical Cancer Research, (2000), 6/6 (2356-2362), 40 reference(s)
CODEN: CCREF4 ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 2000:30399203 BIOTECHNO
AB To test the hypothesis of an association between HER2, and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in patients with advanced breast carcinoma in the setting of a multicenter Phase II trial using paclitaxel and doxorubicin. Serum samples were collected from 58 patients with metastatic breast carcinoma before first-line chemotherapy for advanced disease, and the levels of circulating **HER2 ECD** were measured using an enzyme immunoassay. Immunohistochemistry with anti-HER2 monoclonal **antibody CB11** was used to assess the overexpression of HER2 in the primary tumors. When 450 fmol/ml was used as a cutoff, 24 cases (41%) had elevated HER2 ECD levels. Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; $P = 0.032$ and $P = 0.002$, respectively) but not with variables such as menopausal status, stage at diagnosis, previous adjuvant therapy, or the number of metastatic sites. The levels of circulating HER2 ECD correlated inversely with the response to treatment. The probability of obtaining a complete response to chemotherapy was significantly lower ($P = 0.021$) in patients with elevated HER2 ECD levels (0%; 95% confidence interval, 0-13%) compared with patients with nonelevated HER2 (26%; 95% confidence interval, 12-45%). In addition, the duration of clinical response was significantly shorter in patients with elevated HER2 ECD, compared with the cases with nonelevated HER2 (7.5 versus 11 months; $P = 0.035$). In conclusion, elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination. We suggest that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone.

L19 ANSWER 16 OF 18 USPATFULL on STN

ACCESSION NUMBER: 1998:124659 USPATFULL
TITLE: Immunoglobulin variants
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5821337		19981013
APPLICATION INFO.:	US 1992-934373		19920821 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-715272, filed on 14 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Davis, Minh-Tam		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	3		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	4813		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 18 USPATFULL on STN

ACCESSION NUMBER: 97:61573 USPATFULL
TITLE: Expression of functional antibody fragments
INVENTOR(S): Carter, Paul J., San Francisco, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648237		19970715
APPLICATION INFO.:	US 1995-433781		19950503 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-291323, filed on 16 Aug 1994, now abandoned which is a continuation of Ser. No. US 1991-762292, filed on 19 Sep 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Lucas, John		
LEGAL REPRESENTATIVE:	Lee, Wendy M.		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1,19		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1756		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab' and F(ab')₂ antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 1990:568423 CAPLUS
DOCUMENT NUMBER: 113:168423
TITLE: ELISA for quantitation of the extracellular domain of
p185HER2 in biological fluids
AUTHOR(S): Sias, Patricia E.; Kotts, Claire E.; Vetterlein,
David; Shepard, Mike; Wong, Wai Lee T.
CORPORATE SOURCE: Dep. Immunol., Genentech Inc., So., San Francisco, CA,
94080, USA
SOURCE: Journal of Immunological Methods (1990), 132(1), 73-80
CODEN: JIMMBG; ISSN: 0022-1759
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The HER2/neu proto-oncogene encodes a receptor that belongs to the
tyrosine-specific protein kinase family. A simple, quant. ELISA was
developed that uses 2 monoclonal **antibodies** directed against the
extracellular domain of the HER2 gene product, p185HER2 (**HER2**
ECD). The assay has a detection range of 0.25-120 ng/mL, is
precise and sensitive. The ability of this assay to detect biol. active
rHER2 ECD is demonstrated by its correlation to a growth inhibitory
bioassay. The sandwich ELISA can also accurately quantitate rHER2 ECD in
a mouse and monkey serum. This assay should be useful for quantitating
low levels of circulating rHER2 ECD in animals in which rHER2 ECD is being
used as an antigen for immunotherapy and in patients which shed receptor.

=> file .jacob

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	46.49	58.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.70	-0.70

FILE 'CAPLUS' ENTERED AT 16:13:06 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:13:06 ON 08 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'MEDLINE' ENTERED AT 16:13:06 ON 08 SEP 2004

FILE 'EMBASE' ENTERED AT 16:13:06 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'USPATFULL' ENTERED AT 16:13:06 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> HER2 (3A) (ECD) (12A)antibody

L20	1 FILE CAPLUS
L21	2 FILE BIOSIS
L22	1 FILE MEDLINE
L23	3 FILE EMBASE
L24	16 FILE USPATFULL

TOTAL FOR ALL FILES

L25	23 HER2 (3A) (ECD) (12A) ANTIBODY
-----	-----------------------------------